Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial

Ambrosy, 2014, The global health and economic burden of hospitalizations for HF: lessons learned from hospitalized HF registries, J Am Coll Cardiol, 63, 1123, 10.1016/j.jacc.2013.11.053 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive HF, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 1999, Effect of metoprolol CR/XL in chronic HF: Metoprolol CR/XL Randomised Intervention Trial in Congestive HF (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe HF. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Packer, 1999, Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic HF. ATLAS Study Group, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312 Packer, 2001, Effect of carvedilol on survival in severe chronic HF, N Engl J Med, 344, 1651, 10.1056/NEJM200105313442201 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic HF, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713 Maggioni, 2002, Effects of valsartan on morbidity and mortality in patients with HF not receiving angiotensin-converting enzyme inhibitors, J Am Coll Cardiol, 40, 1414, 10.1016/S0735-1097(02)02304-5 Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic HF: the CHARM-Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1 Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474 Cleland, 2005, The effect of cardiac resynchronization on morbidity and mortality in HF, N Engl J Med, 352, 1539, 10.1056/NEJMoa050496 Bristow, 2004, Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic HF, N Engl J Med, 350, 2140, 10.1056/NEJMoa032423 Bardy, 2005, Amiodarone or an implantable cardioverter-defibrillator for congestive HF, N Engl J Med, 352, 225, 10.1056/NEJMoa043399 Roger, 2004, Trends in HF incidence and survival in a community-based population, JAMA, 292, 344, 10.1001/jama.292.3.344 Levy, 2002, Long-term trends in the incidence of and survival with HF, N Engl J Med, 347, 1397, 10.1056/NEJMoa020265 Go, 2013, Heart disease and stroke statistics—2013 update: a report from the American Heart Association, Circulation, 127, e6, 10.1161/CIR.0b013e31828124ad Heidenreich, 2011, Forecasting the impact of HF in the United States: a policy statement from the American Heart Association, Circulation, 213, 933, 10.1161/CIR.0b013e31820a55f5 Desai, 2010, Connecting the circle from home to heart-failure disease management, N Engl J Med, 363, 2364, 10.1056/NEJMe1011769 Adamson, 2011, CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system, J Card Fail, 17, 3, 10.1016/j.cardfail.2010.08.002 Yancy, 2013, 2013 ACCF/AHA guideline for the management of HF: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128, 1810, 10.1161/CIR.0b013e31829e8807 Abraham, 2011, Wireless pulmonary artery haemodynamic monitoring in chronic HF: a randomised controlled trial, Lancet, 377, 658, 10.1016/S0140-6736(11)60101-3 Adamson, 2014, Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in HF with preserved ejection fraction, Circ Heart Fail, 7, 935, 10.1161/CIRCHEARTFAILURE.113.001229 Benza, 2015, Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor, J Heart Lung Transplant, 34, 329, 10.1016/j.healun.2014.04.014 Krahnke, 2014, HF and respiratory hospitalizations are reduced in HF subjects with chronic obstructive pulmonary disease using an implantable pulmonary artery pressure monitoring device, J Card Fail, 21, 240, 10.1016/j.cardfail.2014.12.008 Raina, 2015, Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system, J Heart Lung Transplant, 34, 438, 10.1016/j.healun.2015.01.983 Castro, 2007, A wireless pressure sensor for monitoring pulmonary artery pressure in advanced HF: initial experience, J Heart Lung Transplant, 26, 85, 10.1016/j.healun.2006.10.006 Verdejo, 2007, Comparison of a radiofrequency-based wireless pressure sensor to Swan-Ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in HF, J Am Coll Cardiol, 50, 2375, 10.1016/j.jacc.2007.06.061 Abraham, 2011, Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with HF, Am Heart J, 161, 558, 10.1016/j.ahj.2010.10.041 Andersen, 1982, Cox's regression model for counting processes, a large sample study, Annal Stat, 10, 1100, 10.1214/aos/1176345976 Castañeda, 2010, Appraisal of several methods to model time to multiple events per subject: modelling time to hospitalizations and death, Rev Colomb Estad, 33, 43 Loh, 2013, Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion HF Monitoring System, J Am Coll Cardiol, 61, 1571, 10.1016/j.jacc.2012.08.1035 Abraham, 2014, Trials of implantable monitoring devices in HF: which design is optimal?, Nat Rev Cardiol, 11, 576, 10.1038/nrcardio.2014.114 Zannad, 2014, Current challenges for clinical trials of cardiovascular medical devices, Int J Cardiol, 175, 30, 10.1016/j.ijcard.2014.05.021 Buyze, 2011, Crossover studies with survival outcomes, Stat Methods Med Res, 25, 1 Wei, 1997, An overview of statistical methods for multiple failure time data in clinical trials, Stat Med, 16, 833, 10.1002/(SICI)1097-0258(19970430)16:8<833::AID-SIM538>3.0.CO;2-2 Hardin, 2003 Gardiner, 2009, Fixed effects, random effects and GEE: what are the differences?, Stat Med, 28, 221, 10.1002/sim.3478 Binanay, 2005, Evaluation study of congestive HF and pulmonary artery catheterization effectiveness: the ESCAPE trial, JAMA, 294, 1625, 10.1001/jama.294.13.1625 Hoeper, 2006, Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers, J Am Coll Cardiol, 48, 2546, 10.1016/j.jacc.2006.07.061 Bourge, 2008, Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced HF: the COMPASS-HF study, J Am Coll Cardiol, 51, 1073, 10.1016/j.jacc.2007.10.061 Stevenson, 2010, Chronic ambulatory intracardiac pressures and future HF events, Circ Heart Fail, 3, 580, 10.1161/CIRCHEARTFAILURE.109.923300 Zile, 2008, Transition from chronic compensated to acute decompensated HF: pathophysiological insights obtained from continuous monitoring of intracardiac pressures, Circulation, 118, 1433, 10.1161/CIRCULATIONAHA.108.783910 Zile, 2011, Hemodynamic factors associated with acute decompensated HF: part 1—Insights into pathophysiology, J Card Fail, 17, 282, 10.1016/j.cardfail.2011.01.010 Adamson, 2011, Hemodynamic factors associated with acute decompensated HF: part 2—Use in automated detection, J Card Fail, 17, 366, 10.1016/j.cardfail.2011.01.011